For the quarter ending 2025-09-30, PRME made $1,225,000 in revenue. -$50,582,000 in net income. Net profit margin of -4129.14%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Collaboration revenue | 1,225,000 | 1,115,000 | 1,454,000 | 466,666.667 |
| Research and development | 43,990,000 | 41,375,000 | 40,562,000 | 35,939,000 |
| General and administrative | 11,208,000 | 13,117,000 | 13,284,000 | 11,729,500 |
| Total operating expenses | 55,198,000 | 54,492,000 | 53,846,000 | 47,668,500 |
| Loss from operations | -53,973,000 | -53,377,000 | -52,392,000 | -46,281,500 |
| Interest income | 1,141,000 | 743,000 | 1,182,000 | 1,107,000 |
| Amortization of premiums and discount on short-term investments | 752,000 | 530,000 | 339,000 | 568,000 |
| Change in fair value of short-term investment related party | 1,454,000 | -505,000 | -1,056,000 | 612,500 |
| Other income, net | 44,000 | 18,000 | 37,000 | 42,500 |
| Total other income, net | 3,391,000 | 786,000 | 502,000 | 2,330,000 |
| Net loss before income taxes | - | -52,591,000 | -51,890,000 | -43,951,500 |
| Provision for income taxes | - | 0 | - | - |
| Net loss attributable to common stockholders, basic | -50,582,000 | -52,591,000 | -51,890,000 | -44,018,500 |
| Net loss attributable to common stockholders, diluted | -50,582,000 | -52,591,000 | -51,890,000 | -44,018,500 |
| Net loss per share attributable to common stockholders, basic (in dollars per share) | -0.32 | -0.41 | -0.4 | -0.375 |
| Net loss per share attributable to common stockholders, diluted (in dollars per share) | -0.32 | -0.41 | -0.4 | -0.375 |
| Weighted-average common shares outstanding, basic (in shares) | 160,503,183 | 129,185,918 | 130,884,490 | -60,176,377.5 |
| Weighted-average common shares outstanding, diluted (in shares) | 160,503,183 | 129,185,918 | 130,884,490 | -60,176,377.5 |
Prime Medicine, Inc. (PRME)
Prime Medicine, Inc. (PRME)